To this end, we first used CRISPR‐Cas9 technology to knockout GLT1D1 in mouse B‐cell lymphoma cells (A20 cell line) and tested cell survival in culture and tumor formation in vivo. This evidence concerns the gene GLT1D1 and B-cell non-Hodgkin lymphoma.